億勝生物科技(01061.HK):預計滴眼液產品二階段三期試驗將於明年二季度完成
格隆匯12月12日丨億勝生物科技(01061.HK)發佈公告,有關公司全資附屬公司Essex Bio-Investment 、Mitotech及俄羅斯Mitotech訂立的共同開發協議,內容有關於第一階段三期試驗的臨牀開發及第二階段三期試驗的建議臨牀開發。誠如此前披露,Essex Bio-Investment已有條件同意根據開發該產品達成的不同里程碑就第二階段三期試驗出資最多2000萬美元。該產品為含SkQ滴眼液,SkQ作為其唯一的活性藥物成分,將提供為乾眼症領域的藥品。
經考慮至今就該產品達成的開發里程碑後,Essex Bio-Investment已根據共同開發協議條款行使其選擇權為第二階段三期試驗出資,且已開始向第一名患者進行第二階段三期試驗。
預期第二階段三期試驗將涉及兩個治療組別,每個治療組別將有約300名患者參與第二階段三期試驗。目前預期第二階段三期試驗將於2020年第二季度或前後完成。集團將遵守上市規則於適當時候公佈第二階段三期試驗結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.